Alessandra Mangia

Summary

Country: Italy

Publications

  1. doi Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis
    A Andriulli
    Division of Gastroenterology, Casa Sollievo della Sofferenza Hospital, IRCCS, San Giovanni Rotondo, Italy
    Aliment Pharmacol Ther 28:397-404. 2008
  2. doi Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies
    Alessandra Mangia
    Liver Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy Electronic address
    Dig Liver Dis 46:S179-85. 2014
  3. doi Treatment optimization and prediction of HCV clearance in patients with acute HCV infection
    Alessandra Mangia
    Liver Unit, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
    J Hepatol 59:221-8. 2013
  4. doi What's new in HCV genotype 2 treatment
    Alessandra Mangia
    Liver Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
    Liver Int 32:135-40. 2012
  5. ncbi Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3
    Alessandra Mangia
    Gastroenterology Unit, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
    N Engl J Med 352:2609-17. 2005
  6. doi Treatment of non-genotype 1 hepatitis C virus patients
    Alessandra Mangia
    Liver Unit, IRCCS, Hospital Casa Sollievo della Sofferenza, 71013, San Giovanni Rotondo, Italy
    Curr Gastroenterol Rep 14:87-93. 2012
  7. doi Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring
    Alessandra Mangia
    Liver Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
    Hepatology 54:772-80. 2011
  8. doi Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3
    Alessandra Mangia
    Liver Unit, IRCCS, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
    J Hepatol 53:1000-5. 2010
  9. ncbi High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis
    Alessandra Mangia
    Division of Gastroenterology, Ospedale Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Italy
    J Hepatol 37:109-16. 2002
  10. ncbi Short-duration therapy for hepatitis C: suitable for all?
    A Mangia
    Division of Gastroenterology, Hospital Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Italy
    J Viral Hepat 14:221-7. 2007

Detail Information

Publications52

  1. doi Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis
    A Andriulli
    Division of Gastroenterology, Casa Sollievo della Sofferenza Hospital, IRCCS, San Giovanni Rotondo, Italy
    Aliment Pharmacol Ther 28:397-404. 2008
    ..Anti-viral therapy seems more successful in HCV genotype 2 than genotype 3-infected patients...
  2. doi Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies
    Alessandra Mangia
    Liver Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy Electronic address
    Dig Liver Dis 46:S179-85. 2014
    ..Sofosbuvir-based combinations are safe and well tolerated without side effects directly related to the drug. A large body of evidence suggests that sofosbuvir marks a revolution in HCV treatment. ..
  3. doi Treatment optimization and prediction of HCV clearance in patients with acute HCV infection
    Alessandra Mangia
    Liver Unit, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
    J Hepatol 59:221-8. 2013
    ....
  4. doi What's new in HCV genotype 2 treatment
    Alessandra Mangia
    Liver Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
    Liver Int 32:135-40. 2012
    ..Existing results suggest that the genetic evaluation of IL28B may be useful in patients with HCV-2 for predicting response in patients without RVR...
  5. ncbi Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3
    Alessandra Mangia
    Gastroenterology Unit, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
    N Engl J Med 352:2609-17. 2005
    ..We hypothesized that in patients with hepatitis C virus (HCV) genotype 2 or 3 in whom HCV RNA is not detectable after 4 weeks of therapy, 12 weeks of treatment is as effective as 24 weeks...
  6. doi Treatment of non-genotype 1 hepatitis C virus patients
    Alessandra Mangia
    Liver Unit, IRCCS, Hospital Casa Sollievo della Sofferenza, 71013, San Giovanni Rotondo, Italy
    Curr Gastroenterol Rep 14:87-93. 2012
    ..Whether a genotype individualized treatment may increase virologic response is the object of current investigations...
  7. doi Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring
    Alessandra Mangia
    Liver Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
    Hepatology 54:772-80. 2011
    ..Few CC patients remained viremic beyond week 8 to allow the analysis of relationships between IL28B type and extended treatment...
  8. doi Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3
    Alessandra Mangia
    Liver Unit, IRCCS, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
    J Hepatol 53:1000-5. 2010
    ..The benefit of individualizing treatment for patients with genotype 3 HCV infection on the basis of viral clearance at week 4 (wk4-R) has not been firmly established...
  9. ncbi High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis
    Alessandra Mangia
    Division of Gastroenterology, Ospedale Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Italy
    J Hepatol 37:109-16. 2002
    ....
  10. ncbi Short-duration therapy for hepatitis C: suitable for all?
    A Mangia
    Division of Gastroenterology, Hospital Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Italy
    J Viral Hepat 14:221-7. 2007
    ..However, some issues on this topic, are still open. In this review, existing evidence is discussed, and both the relevance and limitations of published studies are considered...
  11. doi An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response
    Alessandra Mangia
    Liver Unit, Instituto di Ricovero e Cura a Carattere Scientifico Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
    Gastroenterology 139:821-7, 827.e1. 2010
    ..We evaluated the effects of IL-28B polymorphisms on response to treatment with peginterferon and ribavirin in a well-characterized cohort of genotype 2/3 patients...
  12. doi Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin
    A Mangia
    Division of Gastroenterology, Casa Sollievo della Sofferenza Hospital, IRCCS, San Giovanni Rotondo, Italy
    Aliment Pharmacol Ther 31:1346-53. 2010
    ..The optimal dose of ribavirin to be used in combination with Peg-IFN in patients with HCV genotypes 2 and 3 undergoing short treatment has not been established...
  13. ncbi Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial
    Alessandra Mangia
    Gastroenterology, Istituto di Ricovero e Cura a Carattere Scientifico, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
    Hepatology 47:43-50. 2008
    ..RVR patients with baseline viremia >or=400,000 IU/mL achieved higher SVR rates when treated for 48 weeks rather than 24 weeks (86.8% versus 73.1%, P = 0.14). The only predictive factor of SVR in RVR patients was advanced fibrosis...
  14. doi Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection
    Alessandra Mangia
    Liver Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni, Rotondo, Italy
    Hepatology 49:358-63. 2009
    ..49-4.20] and BMI 30 or higher (odds ratio, 1.7; CI, 1.03-2.70) were independently associated with relapse. Forty-three of 67 patients with relapse agreed to be re-treated, and an SVR was achieved in 30 (70.0%) of them...
  15. doi The use of molecular assays in the management of viral hepatitis
    A Mangia
    Liver Unit, IRCCS, Ospedale Casa Sollievo della Sofferenza San Giovanni Rotondo, Italy
    Dig Liver Dis 40:395-404. 2008
    ..These proceedings have the aim of identifying which molecular tests, among those currently available, meet clinical requirements for each specific application...
  16. ncbi Causes of portal venous thrombosis in cirrhotic patients: the role of genetic and acquired factors
    A Mangia
    Division of Gastroenterology, Hospital Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Italy
    Eur J Gastroenterol Hepatol 17:745-51. 2005
    ..All patients were followed up for a mean period of 18 months (range 10-30)...
  17. ncbi A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C
    A Mangia
    Division of Gastroenterology, Casa Sollievo della Sofferenza Hospital, IRCCS, 71013 San Giovanni Rotondo, Italy
    J Viral Hepat 12:292-9. 2005
    ..In treatment-naive patients with chronic hepatitis C, triple therapy with PEG-IFN alpha-2a, RBV and AMA produces higher SVR than dual or triple therapy with conventional IFN alpha-2a...
  18. doi IL28B CC-genotype association with HLA-DQB1*0301 allele increases the prediction of spontaneous HCV RNA clearance in thalassaemic HCV-infected patients
    Alessandra Mangia
    Liver Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
    Antivir Ther 16:1309-16. 2011
    ....
  19. ncbi Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial
    A Mangi
    Division of Gastroenterology, Ospedale Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Italy
    J Hepatol 34:441-6. 2001
    ..In chronic hepatitis C the schedule of interferon (IFN), 3 MU thrice weekly (tiw) plus ribavirin (1000-1200 mg/daily) needs further evaluation, as IFN dosages >3 MU achieve better responses...
  20. ncbi Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study
    A Mangia
    Division of Gastroenterology, Casa Sollievo della Sofferenza Hospital, IRCCS, S Giovanni Rotondo, Italy
    Aliment Pharmacol Ther 19:331-7. 2004
    ..In patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels, liver fibrosis has been reported in 0-22% of cases and advanced liver disease in 5-10% of cases...
  21. ncbi A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C
    A Mangia
    Division of Gastroenterology and Department of Human Pathology, Ospedale Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Ospedale Canosa, Italy
    Hepatology 33:989-93. 2001
    ..A substantial proportion of naïve patients with chronic hepatitis C have an end-of-treatment and end-of-follow-up virologic and biochemical response to a combination of IFN and AMA. This new treatment appears safe and well tolerated...
  22. ncbi IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infection
    A Mangia
    Division of Gastroenterology, Ospedale Casa Sollievo della Sofferenza, IRCCS, 71013, San Giovanni Rotondo, Italy
    Cytokine 25:103-9. 2004
    ....
  23. doi Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients
    Alessandra Mangia
    Liver Unit, IRCCS Hospital Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
    Liver Int 31:36-41. 2011
    ..Finally, we will face the debated issue of whether the subset of patients with genotype 2 or 3 requires an extended treatment duration...
  24. doi Update on the treatment of patients with non-genotype 1 hepatitis C virus infection
    Alessandra Mangia
    Liver Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
    Clin Infect Dis 56:1294-300. 2013
    ..In patients who do not achieve SVR with ribavirin 800 mg/day for 24 weeks, retreatment with weight-based ribavirin should be considered. The impact of new molecules in development will be discussed...
  25. ncbi Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials
    Alessandra Mangia
    Division of Gastroenterology, Ospedale Casa Sollievo Sofferenza, IRCCS, San Giovanni Rotondo 71013, Italy
    J Hepatol 40:478-83. 2004
    ..We performed a meta-analysis of the individual patient's data from previous studies...
  26. ncbi External validation of biochemical indices for noninvasive evaluation of liver fibrosis in HCV chronic hepatitis
    Angelo Iacobellis
    Division of Gastroenterology, Hospital Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Italy
    Am J Gastroenterol 100:868-73. 2005
  27. pmc Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients
    Alessandra Mangia
    Alessandra Mangia, Leonardo Mottola, Rosanna Santoro, Liver Unit IRCCS, Casa Sollievo della Sofferenza, San Giovanni Rotondo, 71013 Fg, Italy
    World J Gastroenterol 19:8924-8. 2013
    ..Simple size of the studies and GT-2 and GT-3 proportion were discussed. An algorithm for the practical use of IL28B in these patients was suggested at the aim of optimizing treatment. ..
  28. ncbi Short-term treatment duration for HCV-2 and HCV-3 infected patients
    A Andriulli
    Division of Gastroenterology, Casa Sollievo della Sofferenza Hospital, IRCCS, 71013 San Giovanni Rotondo, Italy
    Dig Liver Dis 38:741-8. 2006
    ..We have shown that 12-14 weeks treatment is effective in HCV-2 or -3 patients with undetectable HCV-RNA after 4 weeks of therapy (rapid virologic response)...
  29. doi Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin
    A Andriulli
    Gastroenterology Unit, Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy
    J Viral Hepat 16:28-35. 2009
    ..These results warrant future investigations, as discontinuing ribavirin could lead to considerable savings in cost and quality of life related to over-treatment...
  30. doi Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre study
    Leonardo Mottola
    Liver Unit, Hospital Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy
    Liver Int 35:482-8. 2015
    ..Different prevalence of favourable IL28BCC genotype have been reported in studies performed in different countries around the world. Data on distribution of IL28B genotypes in healthy Italian subjects are lacking...
  31. ncbi Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study
    Savino Bruno
    Liver Unit, Department of Medicine, AO Fatebenefratelli e Oftalmico, Milan, Italy
    Hepatology 45:579-87. 2007
    ..Irrespective of SVR achievement, all patients should continue surveillance because the risk of occurrence of HCC was not entirely avoided...
  32. ncbi Treatment of patients with HCV infection with or without liver biopsy
    A Andriulli
    Division of Gastroenterology, Hospital Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Italy
    J Viral Hepat 11:536-42. 2004
    ..0001) and platelets (P = 0.004) maintained their predictive power. In most patients with HCV infection, virological clearance after therapy can be achieved irrespective of whatever a liver biopsy might show...
  33. doi Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR-{gamma} in Huh-7 cells
    Valerio Pazienza
    Gastroenterology Unit, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo FG, Italy
    J Gen Virol 91:1678-86. 2010
    ..This is the first report proposing a molecular mechanism through which the HCV core protein (genotype 3a) modulates SOCS-7 expression...
  34. ncbi Predictability of monthly and yearly rhythms of breast cancer features
    A Paradiso
    Clinical Experimental Oncology Laboratory, National Oncology Institute of Bari, Italy
    Breast Cancer Res Treat 67:41-9. 2001
    ..We confirmed that breast biology has significant menstrual and seasonal variations and that the seasonality is probably the timing factor more relevant in periodicity determination...
  35. ncbi Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer
    A Paradiso
    Clinical Experimental Oncology Laboratory, Senology Unit, Histopathology Service, and Medical Oncology Unit, National Oncology Institute, Bari, Italy
    J Clin Oncol 19:3929-37. 2001
    ..The aim of the present study was to investigate whether patients with fast-proliferating, node-negative breast cancer could benefit from adjuvant chemotherapy with fluorouracil, epirubicin, and cyclophosphamide (FEC)...
  36. ncbi Failure of primary breast cancer neoangiogenesis to predict pattern of distant metastasis
    A Paradiso
    Clinical Experimental Oncology Laboratory, National Cancer Institute, Bari, Italy
    Clin Exp Med 1:127-32. 2001
    ..98-3.35, P<0.06) by multivariate analysis. In conclusion, the assessment of neoangiogenesis of primary breast cancer by CD34 expression does not provide information predictive of different distant sites of metastasis...
  37. ncbi HLA class II favors clearance of HCV infection and progression of the chronic liver damage
    A Mangia
    Division of Gastroenterology, Hospital Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy
    J Hepatol 30:984-9. 1999
    ..This study was aimed to determine whether host-dependent genetic factors modulate the outcome of HCV infection...
  38. doi Individualized treatment of genotype 1 naïve patients: an italian multicenter field practice experience
    Alessandra Mangia
    Hospital IRCCS Casa Sollievo della Sofferenza, Liver Unit, San Giovanni Rotondo, Italy
    PLoS ONE 9:e110284. 2014
    ..We investigated, among naïve patients, number and characteristics of treatment candidates who were started on triple or dual therapy in comparison to those who were deferred...
  39. ncbi Ultrasonographic and biochemical parameters in the non-invasive evaluation of liver fibrosis in hepatitis C virus chronic hepatitis
    A Iacobellis
    Division of Gastroenterology, Casa Sollievo della Sofferenza Hospital, IRCCS, San Giovanni Rotondo, Italy
    Aliment Pharmacol Ther 22:769-74. 2005
    ..Prior studies suggest that platelet counts of <140 000/microL can discriminate patients with different stages of fibrosis...
  40. ncbi Hepatitis C infection in patients with chronic kidney disease
    A Mangia
    Division of Gastroenterology, General Hospital, IRCCS, San Giovanni Rotondo Italy
    Int J Artif Organs 31:15-33. 2008
    ..Responses to the critical issues have been developed by a consensus of experts, endorsed by the Italian Association for the Study of the Liver (AISF) and some clinical recommendations have been added...
  41. doi High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient's outcome
    Raffaela Barbano
    Laboratory of Oncology, Research Department, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
    Int J Cancer 129:536-45. 2011
    ..Our results suggest that RAD51 expression determination could contribute to a better molecular classification of mammary tumors and may represent a novel tool for evaluating postoperative adjuvant therapy for breast cancer patients...
  42. ncbi HLA and enteric antineuronal antibodies in patients with achalasia
    A Latiano
    U O Gastroenterologia, Ospedale CSS IRCCS, San Giovanni Rotondo, Italy
    Neurogastroenterol Motil 18:520-5. 2006
    ..However, given the association between achalasia and HLA-DQ1, further research is needed to clarify the role of HLA antigens and antineuronal antibodies in this disease...
  43. doi Short treatment to patients with genotype 2 or 3
    Olav Dalgard
    Hepatology 48:694. 2008
  44. ncbi Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV
    Angelo Andriulli
    N Engl J Med 357:1660; author reply 1661-2. 2007
  45. ncbi Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection
    Olav Dalgard
    Department of Microbiology Ullevål University Hospital, Oslo, Norway
    Drugs 66:1807-15. 2006
    ..For patients with genotype 3, a univocal recommendation on treatment duration cannot be made. However, ongoing trials will probably clarify this aspect...
  46. ncbi An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation
    Karim Abid
    Division of Gastroenterology and Hepatology, University Hospital, 24 Rue Micheli du Crest, CH 1211 Geneva, Switzerland
    J Hepatol 42:744-51. 2005
    ..To extend these observations, we established an in vitro model expressing the HCV core of different genotypes...
  47. ncbi Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data
    Gioacchino Leandro
    IRCSS de Bellis, Castellana Grotte, Italy
    Gastroenterology 130:1636-42. 2006
    ..We evaluated the association between steatosis and fibrosis and their common correlates in persons with CHC and in subgroup analyses according to hepatitis C virus (HCV) genotype and body mass index...
  48. pmc Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    J Clin Microbiol 40:3729-34. 2002
    ....
  49. ncbi The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms
    Valerio Pazienza
    Division of Clinical Pathology, University Hospital, Geneva, Switzerland
    Hepatology 45:1164-71. 2007
    ..We confirmed these findings by using agonists for PPARgamma (rosiglitazone) or short interfering RNAs for SOCS-7...
  50. doi Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis
    Tommaso Stroffolini
    Department of Gastroenterology, Ospedale San Giacomo, Roma, Italy
    Am J Gastroenterol 103:1966-72. 2008
    ....
  51. ncbi HCV chronic infection and CCR5-delta32/delta32
    Alessandra Mangia
    Gastroenterology 124:868-9; author reply 869-70. 2003